The Board of Pharmacy is warning licensees to be aware of scam callers claiming to represent the California State Board of Pharmacy or another government agency. In many cases, callers are attempting to extort money or elicit sensitive information — e.g., license numbers, DEA registration numbers, etc. — from licensees.
On Aug. 17, the Department of Health Care Services (DHCS) and its Medi-Cal Rx contractor Magellan posted an updated provider bulletin notifying pharmacy providers of its plan to recommence pharmacy outpatient drug retroactive fee-for-service (FFS) claims adjustments with dates of service from May 2017 through February 2019.
CHA has issued a members-only summary, prepared by Health Policy Alternatives, Inc., of the proposed remedy issued by the Centers for Medicare & Medicaid Services (CMS) for its 340B-acquired drug payment policy that was in effect from 2018-2022 for hospitals paid under the outpatient prospective payment system. The proposal is in response to a remand from the U.S. District Court for the District of Columbia and the U.S. Supreme Court’s decision in American Hospital Association v. Becerra.
As a result of the Supreme Court ruling in American Hospital Association v. Becerra, the Centers for Medicare & Medicaid Services (CMS) issued its proposed remedy for its 340B-acquired drug payment policy that was in effect from 2018-2022. The rule proposes to make a hospital-specific lump sum settlement of an estimated $9 billion to approximately 1,600 340B-eligible hospitals paid under the outpatient prospective payment system (OPPS).